Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Guo, Quan Yi ^a   Yuan, Mei ^a   Peng, Jiang ^a   Cui, Xue Mei ^a   Song, Ge ^a   Sui, Xiang ^a   Lu, Shi Bi ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; LACTATE DEHYDROGENASE; PEPTIDE VACCINE; CANCER VACCINE; HEAT SHOCK PROTEIN; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHROMATOGRAPHY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; LEUKOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SARCOMA; SURVIVAL TIME; T LYMPHOCYTE; TUMOR REGRESSION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CLINICAL PROTOCOL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC PROTOCOLS; CANCER VACCINES; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; FEMALE; HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 79951944535     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-24     Document Type: Article

References (49)

1. The heat-shock proteins. S Lindquist EA Craig, Annu Rev Genet 1988 22 631 677 10.1146/annurev.ge.22.120188.003215 2853609 (Pubitemid 19156675)
2. Molecular chaperones in protein folding and translocation. AR Clarke, Curr Opin Struct Biol 1996 6 43 50 10.1016/S0959-440X(96)80093-5 8696972 (Pubitemid 26073943)
3. Heat Shock Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival. C Giaginis SS Daskalopoulou S Vgenopoulou I Sfiniadakis G Kouraklis SE Theocharis, BMC Gastroenterology 2009 9 14 14 10.1186/1471-230X-9-14 19203381
4. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. M Ogata Z Naito S Tanaka Y Moriyama G Asano, J Nippon Med Sch 2000 67 3 177 185 10.1272/jnms.67.177 10851351
5. Tumor rejection antigens of chemically induced sarcomas of inbred mice. PK Srivastava AB Deleo LJ Old, Proc Natl Acad Sci USA 1986 83 3407 3411 10.1073/pnas.83.10.3407 3458189 (Pubitemid 16043046)
6. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. L Rivoltini C Castelli M Carrabba V Mazzaferro L Pilla V Huber J Coppa G Gallino C Scheibenbogen P Squarcina A Cova R Camerini JJ Lewis PK Srivastava G Parmiani, J Immunol 2003 171 7 3467 74 14500642 (Pubitemid 37254548)
7. Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96. S Janetzki NE Blachere PK Srivastava, J Immuno 1998 21 4 269 276
8. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. H Singh-Jasuja HU Scherer N Hilf D Arnold-Schild HG Rammensee RE Toes H Schild, Eur J Immunol 2000 30 2211 2215 10940912 (Pubitemid 30655760)
9. Immunotherapy of a human papillomavirus(HPV) type 16 E7-expressing tumor by administration of fusion HPV16 E7. NR IChu HB Wu TC Wu LJ Boux LA Mizzen M Siegel, Clin Exp Immunol 2000 121 216 225 10.1046/j.1365-2249.2000.01293.x 10931134
10. Imunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. T Ciupitu Anne-Marie M Petersson K Kono J Charo R Kiessling, Cancer Immuno Immunother 2002 51 163 170 10.1007/s00262-002-0263-9 (Pubitemid 34298112)
11. Immunotherapy of tumor with autologous tumor derived heat shock protein preparations. Y Tamura P Peng K Liu M Daou PK Srivastava, Science 1997 278 3 116 120 10.1126/science.278.5335.117 (Pubitemid 27446289)
12. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. XY Wang MH manjili J Park X Chen E Repasky JR Subjeck, Methods 2004 32 13 20 10.1016/S1046-2023(03)00181-6 14624871 (Pubitemid 37421174)
13. Heat shock proteins as vaccine adjuvants in infections and cancer. BH Segal X-Y Wang CG Dennis R Youn EA Repasky MH Manjili JR Subjeck, Drug Discovery Today 2006 11 11-12 515 519 10.1016/j.drudis.2006.04.016 (Pubitemid 43732542)
14. Heat shock proteins: to present or not, that is the question. CA Gullo G Teoh, Immunology Letters 2004 9491-2 1 10 10.1016/j.imlet.2004.04.002 (Pubitemid 38953706)
15. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. R Gastpar M Gehrmann MA Bausero A Asea C Gross JA Schroeder G Multhoff, Cancer Res 2005 65 5238 5247 10.1158/0008-5472.CAN-04-3804 15958569 (Pubitemid 40827334)
16. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. L Pilla P Squarcina J Coppa V Mazzaferro V Huber D Pende C Maccalli G Sovena L Mariani C Castelli G Parmiani L Rivoltini, Cancer Res 2005 65 3942 3949 10.1158/0008-5472.CAN-04-3493 15867395 (Pubitemid 40616377)
17. Roles of heat-shock proteins in innate and adaptive immunity. Srivastava, Nat Rev Immunol 2002 2 185 194 10.1038/nri749 11913069
18. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Axel Hoos L Levey Daniel, Expert Review of Vaccines 2003 2 3 369 379 10.1586/14760584.2.3.369 12903802 (Pubitemid 36713363)
19. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. A Testori J Richards E Whitman GB Mann J Lutzky L Camacho G Parmiani G Tosti JM Kirkwood A Hoos L Yuh R Gupta PK Srivastava C-100-21 Study Group, J Clin Oncol 2008 26 6 955 62 10.1200/JCO.2007.11.9941 18281670 (Pubitemid 351398090)
20. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. O Eton I Ross Merrick MJ East PF Mansfield N Papadopoulos JA Ellerhorst AY Bedikian JE Lee, Journal of Translational Medicine 2010 8 9 10.1186/1479-5876-8-9 20109236
21. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. C Wood P Srivastava R Bukowski L Lacombe AI Gorelov S Gorelov P Mulders H Zielinski A Hoos F Teofilovici L Isakov R Flanigan R Figlin R Gupta B Escudier the C-100-12 RCC Study Group, Lancet 2008 372 9633 145 154 10.1016/S0140- 6736(08)60697-2 18602688
22. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. V Mazzaferro J Coppa MG Carrabba L Rivoltini M Schiavo E Regalia L Mariani T Camerini A Marchian S Andreola R Camerini M Corsi JJ Lewis PK Srivastava G Parmiani, Clin Cancer Res 2003 9 3235 3245 12960108 (Pubitemid 37082717)
23. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Y Oki P McLaughlin LE Fayad B Pro PF Mansfield GL Clayman LJ Medeiros LW Kwak PK Srivastava A Younes, Cancer 2007 109 1 77 83 10.1002/cncr.22389 17133412 (Pubitemid 46120196)
24. A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use. J Gong Y Zhang J Durfee D Weng C Liu S Koido B Song V Apostolopoulos SK Calderwood, J Immunology 2010 184 1 488 96 10.4049/jimmunol.0902255
25. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. M Graner A Raymond, Cancer Immunol Immunother 2000 49 476 484 10.1007/s002620000138 11092614
26. Primary experimental observation on mice sarcoma with heat shock protein/peptides complex for immunotherapy. Yu Tang XM Cui M Yuan SB Lu, Chin J Cancer Prev Treat 2006 13 9 648 650
27. Therapeutic effects of mixed heat shock protein/peptides on mice sarcoma. XM Cui M Yuan Y Tang SB Lu, ZhongHua ShiYan WaiKe ZaZhi 2006 23 5 636
28. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. L Pilla R Patuzzo L Rivoltini M Maio E Pennacchioli E Lamaj A Maurichi S Massarut A Marchian C Santantonio D Tosi F Arienti A Cova G Sovena A Piris D Nonaka I Bersani A Di Florio M Luigi PK Srivastava A Hoos M Santinami G Parmiani, Cancer Immunol Immunother 2006 55 958 968 10.1007/s00262-005-0084-8 16215718 (Pubitemid 43673585)
29. Macrophages as effective cells in interleukine 12 induced T cell-dependent tumor rejection. KL Tsung JP Dolan LY Tsung, et al. Cancer Res 2002 62 5069 5075 12208763 (Pubitemid 34984436)
30. Interleukin-12 in anti-tumor immunity and immunotherapy. MP Colombo G Trinchieri, Cytokine & Growth Factor Reviews 2002 13 2 155 168 (Pubitemid 34229390)
31. A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma. J-Q Gao T Sugita N Kanagawa K Iida Y Eto Y Motomura H Mizuguchi Y Tsutsumi T Hayakawa T Mayumi S Nakagawa, Biochemical and Biophysical Research Communications 2005 328 4 1043 1050 10.1016/j.bbrc.2005.01.061 15707983 (Pubitemid 40238740)
32. IFN- and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. JM Wigginton E Gruys L Geiselhart J Subleski KL Komschlies Jong-W Park TA Wiltrout K Nagashima TC Back RH Wiltrout, J Clin Invest 2001 108 1 51 62 11435457 (Pubitemid 32634922)
33. Pre-Existing Tumor-Sensitized T Cells are essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12. Le Hop N Lee Natalie C Tsung Kangla Norton Jeffrey A, Journal of Immunology 2001 167 6765 6772
34. Tumor escape mechanism governed by myeloid-derived suppressor cells. S Nagaraj DI Gabrilovich, Cancer Res 2008 68 2561 2563 10.1158/0008-5472.CAN-07- 6229 18413722 (Pubitemid 351556251)
35. Altered macrophage differentiation and immune dysfunction in tumor development. A Sica V Bronte, J Clin Invest 2007 117 1155 1166 10.1172/JCI31422 17476345 (Pubitemid 46718400)
36. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. A Younes B Pro MJ Robertson IW Flinn JE Romaguera F Hagemeister NH Dang P Fiumara EM Loyer FF Cabanillas PW McLaughlin MA Rodriguez F Samaniego, Clin Cancer Res 2004 10 16 5432 8 10.1158/1078-0432.CCR-04-0540 15328181 (Pubitemid 39100480)
37. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. S Wadler D Levy HL Frederickson CI Falkson Y Wang E Weller R Burk G Ho AS Kadish Eastern Cooperative Oncology Group, Gynecol Oncol 2004 92 3 957 64 10.1016/j.ygyno.2003.12.022 14984966 (Pubitemid 38251402)
38. + Regulatory T Cells. S Brode T Raine A Cooke, The Journal of Immunology 2006 177 6603 6612 17082572 (Pubitemid 44715023)
39. Effect of Adenovirus-Mediated Heat Shock Protein Expression and Oncolysis in Combination with Low-Dose Cyclophosphamide Treatment on Antitumor Immune Responses Cancer Research. C Di Paolo Nelson S Tuve S Ni KE Hellström I Hellström A Lieber, 2006 66 960 969 16424031
40. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Taieb N Chaput N Schartz S Roux S Novault C Ménard F Ghiringhelli M Terme AF Carpentier G Darrasse-Jèze F Lemonnier L Zitvogel, J Immunol 2006 176 5 2722 9 16493027
41. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. M Morini A Albini G Lorusso K Moelling B Lu M Cilli S Ferrini DM Noonan, Gene Therapy 2004 11 3 284 291 10.1038/sj.gt.3302175 14737088 (Pubitemid 38220080)
42. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Y Motoyoshi K Kaminoda O Saitoh, Oncol Rep 2006 16 1 141 6 16786137
43. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. G François L Nicolas S Elise A Parcellier C Dominique G Carmen C Bruno M François, Eur J Immunol 2004 34 2 336 44 14768038
44. Defining the ability of cytophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: Creation of a beneficial host microenvironment involving type 1 IFNs and myeloid cells. ML Salem AN Kadima SA EL-Naggar, et al. J Immunother 2007 30 1 40 53 10.1097/01.cji.0000211311.28739.e3 17198082 (Pubitemid 46052202)
45. Heat shock proteins as "danger signals": eukaryotic Hsp60 enhances and accelerates antigen-specific IFN-gamma production in T cells. M Breloer B Dorner SH More, Eur J Immunol 2001 31 7 2051 9 10.1002/1521- 4141(200107)31:7<2051::AID-IMMU2051>3.0.CO;2-H 11449358 (Pubitemid 32640721)
46. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. RL Castelli C Carrabba M Mazzaferro V Pilla L Huber V Coppa J Parmiani P Giorgio, J Immunol 2003 171 7 3467 74 14500642
47. Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells. SH More M Breloer A von Bonin, Int Immunol 2001 13 9 1121 721 10.1093/intimm/13.9.1121 11526092
48. Combined chemoimmunotherapy of solid tumours: Improving vaccines? AK Nowak RA Lake WS Bruce Robinson, Advanced Drug Delivery Reviews 2006 58 8 975 99034 10.1016/j.addr.2006.04.002 17005292
49. Enhancing cancer vaccines with immunomodulators. NL Berinstein, Vaccine 2007 25s 72 b88 10.1016/j.vaccine.2007.06.043